Why the study?
Does antiarrhythmic therapy prevent the development of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Does antiarrhythmic therapy prevent the development of atrial fibrillation in patients with hypertrophic cardiomyopathy?
Clinical parameters can identify HCM patients at risk for AF, which carries a poor prognosis and is not prevented by long-term antiarrhythmic therapy.
No takes yet. Share an insight, caveat, or question.
Clinical parameters may stratify AF risk and prognosis in HCM; leaves open whether antiarrhythmic therapy prevents incident AF.
Guttmann et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: